MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, AMGN made $8,618M in revenue. $1,819M in net income. Net profit margin of 21.11%.

Income Overview

Revenue
$8,618M
Net Income
$1,819M
Net Profit Margin
21.11%
EPS
$3.34
Unit: Million (M) dollars
Revenue Breakdown
    • Other Products
    • Repathaevolocumab
    • Prolia
    • Others
Revenue Breakdown
    • US
    • Non Us
    • Product And Service Other

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
8,618 9,866 9,557 9,179
Cost of sales
2,744 2,976 3,082 3,011
Research and development
1,719 2,142 1,900 1,744
Selling, general and administrative
1,602 1,952 1,720 1,691
Other
-113 76 329 77
Total operating expenses
5,952 7,146 7,031 6,523
Operating income
2,666 2,720 2,526 2,656
Interest expense, net
657 653 685 694
Other income, net
75 -553 2,080 -394
Income before income taxes
2,084 1,514 3,921 1,568
Provision for income taxes
265 181 705 136
Net income
1,819 1,333 3,216 1,432
Basic EPS
3.37 2.478 5.98 2.66
Diluted EPS
3.34 2.45 5.93 2.65
Basic Average Shares
540,000,000 538,000,000 538,000,000 538,000,000
Diluted Average Shares
544,000,000 544,000,000 542,000,000 541,000,000
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
US$1,131M (-10.94%↓ Y/Y)Non Us$397M (5.31%↑ Y/Y)US$465M (35.57%↑ Y/Y)Non Us$411M (31.31%↑ Y/Y)US$461M (-35.97%↓ Y/Y)Non Us$266M (-29.82%↓ Y/Y)US$431M (34.69%↑ Y/Y)Non Us$131M (7.38%↑ Y/Y)US$424M (16.16%↑ Y/Y)Non Us$66M (312.50%↑ Y/Y)US$352M (2.62%↑ Y/Y)Non Us$79M (-15.96%↓ Y/Y)US$221M (-19.05%↓ Y/Y)Non Us$194M (100.00%↑ Y/Y)US$283M (40.80%↑ Y/Y)Non Us$129M (15.18%↑ Y/Y)US$228M (-36.67%↓ Y/Y)Non Us$183M (-11.17%↓ Y/Y)Revenue From ContractWith Customer...$343M (20.35%↑ Y/Y)US$218M (0.93%↑ Y/Y)Non Us$112M (3.70%↑ Y/Y)US$314M (-37.70%↓ Y/Y)Non Us$6M (0.00%↑ Y/Y)Non Us$234M (-6.02%↓ Y/Y)US$77M (-15.38%↓ Y/Y)Non Us$151M (14.39%↑ Y/Y)US$136M (0.74%↑ Y/Y)US$246M (-95.66%↓ Y/Y)Non Us$16M (-99.28%↓ Y/Y)US$188M (-96.68%↓ Y/Y)Non Us$70M (-96.83%↓ Y/Y)Revenue From ContractWith Customer...$255M (8.05%↑ Y/Y)Other Products$1,528M (-7.23%↓ Y/Y)Repathaevolocumab$876M (33.54%↑ Y/Y)Prolia$727M (-33.85%↓ Y/Y)EVENITY$562M (27.15%↑ Y/Y)TEPEZZA$490M (28.61%↑ Y/Y)Otezla$431M (-1.37%↓ Y/Y)BLINCYTO$415M (12.16%↑ Y/Y)Nplate$412M (31.63%↑ Y/Y)Xgeva$411M (-27.39%↓ Y/Y)TEZSPIRE$343M (20.35%↑ Y/Y)Kyprolis$330M (1.85%↑ Y/Y)Enbrel$320M (-37.25%↓ Y/Y)Aranesp$311M (-8.53%↓ Y/Y)Vectibix$287M (7.49%↑ Y/Y)UPLIZNA$262M IMDELLTRAIMDYLLTRA$258M KRYSTEXXA$255M (8.05%↑ Y/Y)Product$8,218M (4.38%↑ Y/Y)Product And ServiceOther$400M (44.93%↑ Y/Y)Total revenues$8,618M (5.76%↑ Y/Y)Operating income$2,666M (126.32%↑ Y/Y)Other income, net$75M (-95.06%↓ Y/Y)Total operatingexpenses$5,952M (-14.62%↓ Y/Y)Other-$113M (-113.61%↓ Y/Y)Income before incometaxes$2,084M (5.63%↑ Y/Y)Interest expense, net$657M (-9.13%↓ Y/Y)Cost of sales$2,744M (-7.55%↓ Y/Y)Research and development$1,719M (15.68%↑ Y/Y)Selling, general andadministrative$1,602M (-5.04%↓ Y/Y)Net income$1,819M (5.14%↑ Y/Y)Provision for income taxes$265M (9.05%↑ Y/Y)

amgen-blue-svg

AMGEN INC (AMGN)

amgen-blue-svg

AMGEN INC (AMGN)